Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Pfizer
Modality
gene_therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03861273CT.gov A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | — | Active Not Recruiting | — | — | — |
NCT03307980CT.gov Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | — | Active Not Recruiting | — | — | — |
NCT02484092CT.gov A Gene Therapy Study for Hemophilia B | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| pf-06838435 (this asset) | Pfizer | P3 | B · 62 |
| Factor Ix | CSL Behring | P4 | A |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Nonacog Alfa | Pfizer | P4 | A |
| Nonacog Beta Pegol | Novo Nordisk A/S | P3 | A |
| Coagulation Factor Viia | American Thrombosis and Hemostasis Network | P4 | BBB |
| Albutrepenonacog Alfa | CSL Behring | P3 | BBB |
| Fitusiran | Genzyme, a Sanofi Company | P3 | BBB |
| Bax 326 | Baxalta now part of Shire | P3 | BB |
+40 more in the Hemophilia B cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. pf-06838435 in Hemophilia B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pf-06838435-hemophilia-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →